第1屆
Targeting Cancer Stem Cells in Oncology
-有關癌治療之癌幹細胞標的化的討論會-
期待開發出特效藥
2月19日∼20日
Molecular Medicine Tri-Conference重加入此討論會，反映出作為癌治療藥標的，在製藥業界和生物技術業界中，對癌幹細胞(CSC)及相關路徑的關心高漲之狀況。此討論會預定由業界有關人員發表個案研究，從各種充實性腫瘤分離癌幹細胞，賦予特徵（從生染色體組及蛋白質體（Proteome）面）研究的最新成果、特定CSC自我再生需要的路徑、在CSC內進行藥標的之特定和驗證的試管試驗（in vitro assay）、開發癌治療藥候選的體外（in vitro）效能模式、檢證以癌的信號（Notch、Hedgehog、Wnt等）傳達系作為標的專案的主題。
Who should attend: Scientists from pharma, biotech and academia working on cancer biology, stem cell biology and regenerative medicine
Topics will include, but are not limited to:
- Targeting cancer signaling pathways
- Notch
- Hedgehog
- Wnt
- Isolation and characterization of cancer stem cells
- Genomic and proteomic studies
- In vitro assays for CSC target identification and validation
- In vivo efficacy models
The deadline for submission is July 29, 2011.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
